Cover Image

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist used for the treatment of castration-resistant prostate cancer (CRPC) and reportedly prolongs survival time within a year of starting therapy. However, CRPC patients can develop ENZ resistance (ENZR), mainly driven by abnorm...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Li (Author), Ya Chu (Author), Guangjiang Shi (Author), Xiaobin Wang (Author), Wanli Ye (Author), Chun Shan (Author), Dajia Wang (Author), Di Zhang (Author), Wei He (Author), Jingwei Jiang (Author), Shuqian Ma (Author), Yuhong Han (Author), Zhili Zhao (Author), Shijia Du (Author), Zhen Chen (Author), Zhiyu Li (Author), Yong Yang (Author), Chen Wang (Author), Xi Xu (Author), Hongxi Wu (Author)
Format: Book
Published: Elsevier, 2022-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items